IN2014DN01795A - - Google Patents

Download PDF

Info

Publication number
IN2014DN01795A
IN2014DN01795A IN1795DEN2014A IN2014DN01795A IN 2014DN01795 A IN2014DN01795 A IN 2014DN01795A IN 1795DEN2014 A IN1795DEN2014 A IN 1795DEN2014A IN 2014DN01795 A IN2014DN01795 A IN 2014DN01795A
Authority
IN
India
Prior art keywords
methods
ligands
screening
differentially
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Björn Frendéus
Jenny Mattsson
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Publication of IN2014DN01795A publication Critical patent/IN2014DN01795A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
IN1795DEN2014 2011-09-22 2012-09-20 IN2014DN01795A (cg-RX-API-DMAC10.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1116364.9A GB201116364D0 (en) 2011-09-22 2011-09-22 Screening methods and uses thereof
PCT/EP2012/068576 WO2013041643A1 (en) 2011-09-22 2012-09-20 Screening methods and uses thereof

Publications (1)

Publication Number Publication Date
IN2014DN01795A true IN2014DN01795A (cg-RX-API-DMAC10.html) 2015-05-15

Family

ID=44937671

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1795DEN2014 IN2014DN01795A (cg-RX-API-DMAC10.html) 2011-09-22 2012-09-20

Country Status (17)

Country Link
US (1) US10191049B2 (cg-RX-API-DMAC10.html)
EP (1) EP2758532B1 (cg-RX-API-DMAC10.html)
JP (2) JP6370220B2 (cg-RX-API-DMAC10.html)
KR (1) KR102024125B1 (cg-RX-API-DMAC10.html)
CN (2) CN103827302A (cg-RX-API-DMAC10.html)
AU (1) AU2012311542B2 (cg-RX-API-DMAC10.html)
CA (1) CA2848932C (cg-RX-API-DMAC10.html)
DK (1) DK2758532T3 (cg-RX-API-DMAC10.html)
ES (1) ES2690783T3 (cg-RX-API-DMAC10.html)
GB (1) GB201116364D0 (cg-RX-API-DMAC10.html)
HU (1) HUE040567T2 (cg-RX-API-DMAC10.html)
IN (1) IN2014DN01795A (cg-RX-API-DMAC10.html)
PL (1) PL2758532T3 (cg-RX-API-DMAC10.html)
PT (1) PT2758532T (cg-RX-API-DMAC10.html)
RU (1) RU2622089C2 (cg-RX-API-DMAC10.html)
SI (1) SI2758532T1 (cg-RX-API-DMAC10.html)
WO (1) WO2013041643A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2392723B (en) 2002-09-04 2005-01-12 Bioinvent Int Ab Screening methods
US10575515B2 (en) 2010-05-04 2020-03-03 The General Hospital Corporation Methods and compositions for preserving tissues and organs
GB201116364D0 (en) 2011-09-22 2011-11-02 Bioinvent Int Ab Screening methods and uses thereof
WO2015076355A1 (ja) * 2013-11-22 2015-05-28 株式会社Molcure 標的分子に結合するポリペプチドの決定方法及び決定システム
JP6687601B2 (ja) 2014-08-07 2020-04-22 ザ ジェネラル ホスピタル コーポレイション 全血サンプルの安定化
CN109651506B (zh) * 2017-10-11 2021-12-07 上海交通大学 一种快速获得抗原特异性抗体的方法
EP4537337A1 (en) * 2022-06-13 2025-04-16 BioInvent International AB Methods of isolating anti-ligands

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366862A (en) 1990-02-14 1994-11-22 Receptor Laboratories, Inc. Method for generating and screening useful peptides
ES2109945T3 (es) 1990-06-01 1998-02-01 Chiron Corp Composiciones y procedimientos para identificar moleculas biologicamente activas.
CA2180140A1 (en) 1993-12-27 1995-07-06 Jeffrey I. Weitz Methods and compositions for inhibiting thrombogenesis
US6794128B2 (en) 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
PT1157041E (pt) 1999-03-01 2005-10-31 Genentech Inc Anticorpos para terapia e diagnostico de cancro
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
AU2002220236A1 (en) 2000-11-09 2002-05-21 Bionova Pharmaceutials, Inc. A method for identifying the proteome of cells using an antibody library microarray
GB2392723B (en) * 2002-09-04 2005-01-12 Bioinvent Int Ab Screening methods
CN100575489C (zh) * 2003-05-14 2009-12-30 多曼蒂斯有限公司 从多肽全能文库恢复可逆可解折叠多肽的方法
JP4889493B2 (ja) 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
GB0422431D0 (en) * 2004-10-08 2004-11-10 Affitech As Method
WO2009079793A1 (en) * 2007-12-21 2009-07-02 National Research Council Of Canada Non-aggregating human vh domains
GB201116364D0 (en) 2011-09-22 2011-11-02 Bioinvent Int Ab Screening methods and uses thereof

Also Published As

Publication number Publication date
KR20140080504A (ko) 2014-06-30
GB201116364D0 (en) 2011-11-02
PT2758532T (pt) 2018-11-07
RU2622089C2 (ru) 2017-06-09
WO2013041643A1 (en) 2013-03-28
JP6370220B2 (ja) 2018-08-08
JP2018154627A (ja) 2018-10-04
HUE040567T2 (hu) 2019-03-28
ES2690783T3 (es) 2018-11-22
US20140227249A1 (en) 2014-08-14
CN107663238A (zh) 2018-02-06
AU2012311542B2 (en) 2017-09-21
DK2758532T3 (en) 2018-10-22
CN103827302A (zh) 2014-05-28
CA2848932A1 (en) 2013-03-28
AU2012311542A1 (en) 2014-03-20
EP2758532A1 (en) 2014-07-30
JP2015501289A (ja) 2015-01-15
SI2758532T1 (sl) 2018-12-31
PL2758532T3 (pl) 2018-12-31
RU2014115956A (ru) 2015-10-27
KR102024125B1 (ko) 2019-09-23
US10191049B2 (en) 2019-01-29
CA2848932C (en) 2020-12-29
HK1200486A1 (en) 2015-08-07
EP2758532B1 (en) 2018-07-11

Similar Documents

Publication Publication Date Title
MX2019008211A (es) Estructuras fibrosas que comprenden particulas y metodos para fabricarlas.
GB2509433B (en) Identifying data items
EP2697648A4 (en) SYSTEM FOR DETECTING A SAMPLE ON A BIOPUCE
MX2014009751A (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
EP2841603A4 (en) METHODS OF ASSESSING THE STATUS OF LUNG CANCER
ZA201209179B (en) Hydrocarbon gas processing
IL237794B (en) New ligands for rig-i and methods for their preparation
LT2558577T (lt) Bifunkciniai kompleksai ir tokių kompleksų gamybos ir naudojimo būdai
EP2714971A4 (en) METHOD FOR DETERMINING, IDENTIFYING AND INSULATING CELL-PENETRATING PEPTIDES
ZA201300795B (en) Use of sigma ligands in opioid-induced hyperalgesia
IN2015DN00636A (cg-RX-API-DMAC10.html)
SG11201500600VA (en) Systems and methods for analyzing microbiological substances
GB201116364D0 (en) Screening methods and uses thereof
SG11201501839VA (en) In-line sand screen gauge carrier
WO2013049398A3 (en) Protein-protein interaction as biomarkers
PT2681532E (pt) Determinação de adn e/ou arn a partir de dados de espetrofotómetro uv-vis
GB2523693B (en) Materials and methods for determining susceptibility or predisposition to cancer
ZA201407867B (en) Ore analysis system
WO2011153485A3 (en) Use of the sparc microenvironment signature in the treatment of cancer
EP2925484A4 (en) CONNECTION METHOD FOR METALLIC MASSIVE GLASSES
EP2844267A4 (en) BROAD SPECTRUM ERBB LIGAND BINDING MOLECULES AND METHODS OF USING THE SAME
AU2012903446A0 (en) MR1 ligand and uses therefor
AU2012902899A0 (en) MR1 ligand and uses therefor
GB201200031D0 (en) DNA determination from UV-VIS spectrophotometer data
AU2012904386A0 (en) MR1 Ligand and Uses Therefor-II